Biochemical bone markers in patients with multiple myeloma

Area of Science:

• Biochemistry
• Oncology
• Bone Metabolism

Background:

• Enhanced bone resorption is a hallmark of multiple myeloma (MM).
• Accurate assessment of bone turnover is crucial for managing MM patients.
• Newer biochemical markers offer potential for improved monitoring.

Purpose of the Study:

• To evaluate novel biochemical markers for assessing bone resorption in multiple myeloma.
• To compare bone formation and resorption markers in MM patients and healthy controls.
• To determine the sensitivity of these markers in differentiating MM subgroups.

Main Methods:

• Studied 17 MM patients (male/female, various treatment statuses) and 15 controls.
• Measured serum bone-specific alkaline phosphatase (BSALP), osteocalcin (OC), procollagen type 1 C-terminal peptide (PICP) for bone formation.
• Measured serum tartrate-resistant acid phosphatase (TRAP), urinary deoxypyridinoline (Dpyr), and calcium (Ca) for bone resorption.

Main Results:

• Urinary Dpyr excretion was significantly higher in untreated male MM patients compared to controls.
• The ratios (Dpyr/Cr)/BSALP and (Dpyr/Cr)/PICP were significantly elevated in untreated male MM patients versus controls.
• These marker ratios also effectively distinguished untreated MM patients from those in remission or responding to treatment.

Conclusions:

• Urinary deoxypyridinoline (Dpyr) is a sensitive marker for evaluating bone resorption in multiple myeloma.
• The ratios of (Dpyr/Cr)/BSALP or (Dpyr/Cr)/PICP demonstrate superior sensitivity in differentiating untreated MM patients.
• Combination of these markers shows promise for improved management of multiple myeloma patients.